Journal
FRONTIERS IN IMMUNOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.01480
Keywords
hepatitis C; vaccines; antibodies; T cells; reinfection
Categories
Funding
- Canadian Institutes of Health Research (CIHR) [MOP-133680]
- National Institutes of Health [5U01AI131313-02, 1R01AI136533-01]
- Alberta Innovates-Health Solutions
- Canadian Network on Hepatitis C (CanHepC)
- CIHR [NHC-142832]
- Public Health Agency of Canada
Ask authors/readers for more resources
The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct-acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next-generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available